26 research outputs found

    Π‘ΠΎΠ²Ρ€Π΅ΠΌΠ΅Π½Π½Ρ‹Π΅ ΠΏΠΎΠ΄Ρ…ΠΎΠ΄Ρ‹ ΠΊ классификации топичСских Π³Π»ΡŽΠΊΠΎΠΊΠΎΡ€Ρ‚ΠΈΠΊΠΎΡΡ‚Π΅Ρ€ΠΎΠΈΠ΄ΠΎΠ² Π² Россиии Π·Π°Ρ€ΡƒΠ±Π΅ΠΆΠΎΠΌ

    Get PDF
    The article analyzes current classifications of topical glucocorticosteroid drugs. It also describes advantages and disadvantages of current classifications, emphasizes the expediency of assessing not only the efficacy of the active ingredient but also its skin concentration taking into consideration the base, trade name of the drug and particular features of its biotransformation in the skin.Π”Π°Π½ Π°Π½Π°Π»ΠΈΠ· ΡΡƒΡ‰Π΅ΡΡ‚Π²ΡƒΡŽΡ‰ΠΈΡ… классификаций топичСских Π³Π»ΡŽΠΊΠΎΠΊΠΎΡ€Ρ‚ΠΈΠΊΠΎΡΡ‚Π΅Ρ€ΠΎΠΈΠ΄Π½Ρ‹Ρ… ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ². ΠžΡΠ²Π΅Ρ‰Π΅Π½Ρ‹ достоинства ΠΈ нСдостатки извСстных классификаций. ΠžΡ‚ΠΌΠ΅Ρ‡Π΅Π½Π° Ρ†Π΅Π»Π΅ΡΠΎΠΎΠ±Ρ€Π°Π·Π½ΠΎΡΡ‚ΡŒ ΠΎΡ†Π΅Π½ΠΊΠΈ активности Π΄Π΅ΠΉΡΡ‚Π²ΡƒΡŽΡ‰Π΅Π³ΠΎ вСщСства, Π΅Π³ΠΎ ΠΊΠΎΠ½Ρ†Π΅Π½Ρ‚Ρ€Π°Ρ†ΠΈΠΈ Π² ΠΊΠΎΠΆΠ΅ с ΡƒΡ‡Π΅Ρ‚ΠΎΠΌ основы, коммСрчСского названия лСкарствСнного ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚Π°, Π° Ρ‚Π°ΠΊΠΆΠ΅ особСнностСй биотрансформации Π² ΠΊΠΎΠΆΠ΅

    ΠœΠΈΠΊΡ€ΠΎΠ±Π½Π°Ρ экзСма: соврСмСнныС возмоТности топичСской Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ с использованиСм ΡΡƒΠ»ΡŒΡ„Π°Ρ‚ΠΈΠ°Π·ΠΎΠ»Π° сСрСбра

    Get PDF
    Goal. The authors conducted a comparative assessment of the efficacy and safety of 2% silver sulfathiazole in a prospective parallel-group observational study of patients with microbial eczema at the exacerbation stage. Materials and methods. The efficacy of the therapy was assessed on Day 7 and Day 14 based on dynamic calculations of the EASI index and ultrasonic assessment of the intensity of pathological processes in the epidermis and derma; the life quality was assessed based on DLQI and EQ-5D indices, respectively. The microbial composition in the lesions was assessed based on bacterioscopy tests of the contents of blains and erosion fluids. The safety of the therapy was assessed based on the frequency of adverse effects. Results. The administration of 2% silver sulfathiazole arrested both eczematous and pyogenic processes in the lesions within a short period of time, which was confirmed by ultrasonic tests: the depth and density of epidermis and derma were normalized. When applications were performed twice a day, the efficacy with regard to gram-positive bacteria was higher as compared to β€œclassical” topical antibiotics. An evident therapeutic effect with regard to gram-positive bacteria and absence of adverse effects substantially improved the life quality of patients suffering from microbial eczema.ΠŸΡ€ΠΎΠ²Π΅Π΄Π΅Π½Π° ΡΡ€Π°Π²Π½ΠΈΡ‚Π΅Π»ΡŒΠ½Π°Ρ ΠΎΡ†Π΅Π½ΠΊΠ° эффСктивности ΠΈ бСзопасности использования 2% ΡΡƒΠ»ΡŒΡ„Π°Ρ‚ΠΈΠ°Π·ΠΎΠ»Π° сСрСбра Π² проспСктивном Π½Π°Π±Π»ΡŽΠ΄Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠΌ исслСдовании Π² ΠΏΠ°Ρ€Π°Π»Π»Π΅Π»ΡŒΠ½Ρ‹Ρ… Π³Ρ€ΡƒΠΏΠΏΠ°Ρ… Π»ΠΈΡ† с ΠΌΠΈΠΊΡ€ΠΎΠ±Π½ΠΎΠΉ экзСмой Π² Ρ„Π°Π·Π΅ обострСния. Π­Ρ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ Π½Π° 7-ΠΉ ΠΈ 14-ΠΉ Π΄Π½ΠΈ с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ динамичСского расчСта индСкса EASI ΠΈ ΡƒΠ»ΡŒΡ‚Ρ€Π°ΡΠΎΠ½ΠΎΠ³Ρ€Π°Ρ„ΠΈΡ‡Π΅ΡΠΊΠΎΠΉ ΠΎΡ†Π΅Π½ΠΊΠΈ стСпСни выраТСнности патологичСских процСссов Π² эпидСрмисС ΠΈ Π΄Π΅Ρ€ΠΌΠ΅; качСство ΠΆΠΈΠ·Π½ΠΈ - соотвСтствСнно ΠΏΠΎ значСниям индСксов DLQI ΠΈ EQ-5D. О составС ΠΌΠΈΠΊΡ€ΠΎΠΎΡ€Π³Π°Π½ΠΈΠ·ΠΌΠΎΠ² Π² ΠΎΡ‡Π°Π³Π°Ρ… пораТСния судили ΠΏΠΎ Π΄Π°Π½Π½Ρ‹ΠΌ бактСриоскопичСского исслСдования содСрТимого пустул ΠΈ отдСляСмого эрозий. Π‘Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ‚ΡŒ прСдпринятой Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ частотС возникновСния нСблагоприятных ΠΏΠΎΠ±ΠΎΡ‡Π½Ρ‹Ρ… эффСктов. Показано, Ρ‡Ρ‚ΠΎ ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ 2% ΡΡƒΠ»ΡŒΡ„Π°Ρ‚ΠΈΠ°Π·ΠΎΠ»Π° сСрСбра позволяло Π² ΠΊΠΎΡ€ΠΎΡ‚ΠΊΠΈΠ΅ сроки ΠΊΡƒΠΏΠΈΡ€ΠΎΠ²Π°Ρ‚ΡŒ ΠΊΠ°ΠΊ экзСматозныС, Ρ‚Π°ΠΊ ΠΈ ΠΏΠΈΠΎΠ³Π΅Π½Π½Ρ‹Π΅ процСссы Π² ΠΎΡ‡Π°Π³Π°Ρ… пораТСния, Ρ‡Ρ‚ΠΎ ΠΏΠΎΠ΄Ρ‚Π²Π΅Ρ€ΠΆΠ΄Π°Π»ΠΎΡΡŒ ΡƒΠ»ΡŒΡ‚Ρ€Π°ΡΠΎΠ½ΠΎΠ³Ρ€Π°Ρ„ΠΈΡ‡Π΅ΡΠΊΠΈ Π½ΠΎΡ€ΠΌΠ°Π»ΠΈΠ·Π°Ρ†ΠΈΠ΅ΠΉ Π·Π½Π°Ρ‡Π΅Π½ΠΈΠΉ Ρ‚ΠΎΠ»Ρ‰ΠΈΠ½Ρ‹ ΠΈ плотности эпидСрмиса ΠΈ Π΄Π΅Ρ€ΠΌΡ‹. ΠŸΡ€ΠΈ Π΄Π²ΡƒΠΊΡ€Π°Ρ‚Π½ΠΎΠΌ Π΅ΠΆΠ΅Π΄Π½Π΅Π²Π½ΠΎΠΌ нанСсСнии ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Π² ΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΠΈ Π³Ρ€Π°ΠΌΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΌΠΈΠΊΡ€ΠΎΠ±Π½Ρ‹Ρ… Π°Π³Π΅Π½Ρ‚ΠΎΠ² Π±Ρ‹Π»Π° Π²Ρ‹ΡˆΠ΅ Ρ‚Π°ΠΊΠΎΠ²ΠΎΠΉ Ρƒ «классичСских» мСстных Π°Π½Ρ‚ΠΈΠ±ΠΈΠΎΡ‚ΠΈΠΊΠΎΠ². ΠžΡ‚Ρ‡Π΅Ρ‚Π»ΠΈΠ²Ρ‹ΠΉ тСрапСвтичСский эффСкт Π² ΠΎΡ‚Π½ΠΎΡˆΠ΅Π½ΠΈΠΈ Π³Ρ€Π°ΠΌΠΏΠΎΠ»ΠΎΠΆΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ состава ΠΌΠΈΠΊΡ€ΠΎΡ„Π»ΠΎΡ€Ρ‹ ΠΈ отсутствиС Π½Π΅ΠΆΠ΅Π»Π°Ρ‚Π΅Π»ΡŒΠ½Ρ‹Ρ… ΠΏΠΎΠ±ΠΎΡ‡Π½Ρ‹Ρ… явлСний позволяли Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ ΠΏΠΎΠ²Ρ‹ΡΠΈΡ‚ΡŒ качСство ΠΆΠΈΠ·Π½ΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… с ΠΌΠΈΠΊΡ€ΠΎΠ±Π½ΠΎΠΉ экзСмой

    ΠšΠ»ΠΈΠ½ΠΈΡ‡Π΅ΡΠΊΠ°Ρ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ примСнСния УЀА1-Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π² комплСксном Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ хроничСских Π΄Π΅Ρ€ΠΌΠ°Ρ‚ΠΎΠ·ΠΎΠ²

    Get PDF
    The authors present the results of application of UVA1-therapy in complex treatment of patients with atopic dermatitis, psoriasis and scleroderma. Course of treatment has made 20 procedures of UVA1-therapy with the maximum single dose of irradiation 40 J/ш 2. The general dose of an irradiation 130β€”400 J/ш 2. Comparison groups received medical therapy with usage of standard doses and reception schemes, and did not differ from the basic groups on age of patients, duration and the disease form. Clinical efficiency estimated on dynamics of indexes SCORAD, PAS! and results of ultrasonic scanning of the scleroderma zones. High efficiency and safety of UVA1-therapy in complex treatment atopic dermatitis, psoriasis and scleroderma is established.ΠŸΡ€Π΅Π΄ΡΡ‚Π°Π²Π»Π΅Π½Ρ‹ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ примСнСния Π² комплСксном Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… атопичСским Π΄Π΅Ρ€ΠΌΠ°Ρ‚ΠΈΡ‚ΠΎΠΌ, псориазом, склСродСрмиСй дальнСй Π΄Π»ΠΈΠ½Π½ΠΎΠ²ΠΎΠ»Π½ΠΎΠ²ΠΎΠΉ Π£Π€-Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ (УЀА1). ΠšΡƒΡ€Ρ лСчСния составил 20 ΠΏΡ€ΠΎΡ†Π΅Π΄ΡƒΡ€ УЀА1-Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ с максимальной Ρ€Π°Π·ΠΎΠ²ΠΎΠΉ Π΄ΠΎΠ·ΠΎΠΉ облучСния 40 Π”ΠΆ/см 2. ΠžΠ±Ρ‰Π°Ρ Π΄ΠΎΠ·Π° облучСния 130β€”400 Π”ΠΆ/см 2. Π“Ρ€ΡƒΠΏΠΏΡ‹ сравнСния ΠΏΠΎΠ»ΡƒΡ‡Π°Π»ΠΈ Ρ‚Π΅Ρ€Π°ΠΏΠΈΡŽ лСкарствСнными ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚Π°ΠΌΠΈ с использованиСм стандартных Π΄ΠΎΠ· ΠΈ схСм ΠΏΡ€ΠΈΠ΅ΠΌΠ° ΠΈ Π½Π΅ ΠΎΡ‚Π»ΠΈΡ‡Π°Π»ΠΈΡΡŒ ΠΎΡ‚ основных Π³Ρ€ΡƒΠΏΠΏ ΠΏΠΎ возрасту ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ², Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΠΈ Ρ„ΠΎΡ€ΠΌΠ΅ заболСвания. ΠšΠ»ΠΈΠ½ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ индСксов SCoRAD, PASI, Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π°ΠΌ ΡƒΠ»ΡŒΡ‚Ρ€Π°Π·Π²ΡƒΠΊΠΎΠ²ΠΎΠ³ΠΎ сканирования ΠΎΡ‡Π°Π³ΠΎΠ² склСродСрмии. УстановлСна высокая ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡ‚ΡŒ УЀА1-Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π² комплСксном Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ атопичСского Π΄Π΅Ρ€ΠΌΠ°Ρ‚ΠΈΡ‚Π° ΠΈ склСродСрмии

    Π”Π»ΠΈΡ‚Π΅Π»ΡŒΠ½Π°Ρ тСрапия Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… с тяТСлым Ρ‚Π΅Ρ‡Π΅Π½ΠΈΠ΅ΠΌ Π°ΠΊΠ½Π΅: Π²Ρ‹Π±ΠΎΡ€ Π΄ΠΎΠ· ΠΈ схСм ΠΏΡ€ΠΈΠ΅ΠΌΠ° систСмного ΠΈΠ·ΠΎΡ‚Ρ€Π΅Ρ‚ΠΈΠ½ΠΎΠΈΠ½Π°

    Get PDF
    The article presents current data on the application of a systemic retinoid, isotretinoin, on the basis of the Lidose system for the treatment of patients with severe forms of acne. It also discusses issues of optimization of the daily dose of isotretinoin taking into consideration long-term clinical efficacy and safety of the therapy. The article presents the results of the authors’ study demonstrating the possibility to select mainly large or small doses of systemic isotretinoin depending on the treatment duration.ΠŸΡ€ΠΈΠ²ΠΎΠ΄ΡΡ‚ΡΡ соврСмСнныС Π΄Π°Π½Π½Ρ‹Π΅ ΠΎ ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ систСмного Ρ€Π΅Ρ‚ΠΈΠ½ΠΎΠΈΠ΄Π° ΠΈΠ·ΠΎΡ‚Ρ€Π΅Ρ‚ΠΈΠ½ΠΎΠΈΠ½Π° Π½Π° основС систСмы Lidose Π² Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… с тяТСлыми Ρ„ΠΎΡ€ΠΌΠ°ΠΌΠΈ Π°ΠΊΠ½Π΅. ΠžΠ±ΡΡƒΠΆΠ΄Π°ΡŽΡ‚ΡΡ вопросы ΠΎΠΏΡ‚ΠΈΠΌΠΈΠ·Π°Ρ†ΠΈΠΈ суточной Π΄ΠΎΠ·Ρ‹ ΠΈΠ·ΠΎΡ‚Ρ€Π΅Ρ‚ΠΈΠ½ΠΎΠΈΠ½Π° с ΡƒΡ‡Π΅Ρ‚ΠΎΠΌ долгосрочной клиничСской эффСктивности ΠΈ бСзопасности ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ. ΠŸΡ€ΠΈΠ²ΠΎΠ΄ΡΡ‚ΡΡ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ собствСнного исслСдования, Π΄Π΅ΠΌΠΎΠ½ΡΡ‚Ρ€ΠΈΡ€ΡƒΡŽΡ‰ΠΈΠ΅ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡ‚ΡŒ Π²Ρ‹Π±ΠΎΡ€Π° прСимущСствСнно Π±ΠΎΠ»ΡŒΡˆΠΈΡ…, Π»ΠΈΠ±ΠΎ ΠΌΠ°Π»Ρ‹Ρ… Π΄ΠΎΠ· систСмного ΠΈΠ·ΠΎΡ‚Ρ€Π΅Ρ‚ΠΈΠ½ΠΎΠΈΠ½Π° Π² зависимости ΠΎΡ‚ Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ прСдпринятого лСчСния

    Π­Ρ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ примСнСния узкополосной срСднСволновой ΡƒΠ»ΡŒΡ‚Ρ€Π°Ρ„ΠΈΠΎΠ»Π΅Ρ‚ΠΎΠ²ΠΎΠΉ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ 311 Π½ΠΌ ΠΏΡ€ΠΈ атопичСском Π΄Π΅Ρ€ΠΌΠ°Ρ‚ΠΈΡ‚Π΅ Ρƒ Π΄Π΅Ρ‚Π΅ΠΉ

    Get PDF
    The article presents the results of using a narrow-band mid-wavelength ultraviolet therapy (311 nm) in 79 children suffering from with atopic dermatitis. The course of treatment comprised 15 to 20 sessions of ultraviolet therapy with the maximal dose of irradiation being not more than 0.15 J/cm2. The control group (n=35) received traditional therapeutic treatment with the use of standard schemes of dosing and drug administration, and did not differ from the main group of patients in age, duration or form of the disease. Clinical efficacy of the therapy was estimated according to the SCORAD index, Dermatological Index of the Symptom Scale and Children's Dermatology Life Quality Index. The efficacy of the narrow-band mid-wavelength ultraviolet therapy (311 nm) turned out to be very high, which is confirmed by earlier reduction of clinical symptoms among patients from this group than in the control group. The latter fact was also confirmed by the reduction of absolute values of the SCORAD index and Dermatological Index of the Symptom Scale (pΠŸΡ€Π΅Π΄ΡΡ‚Π°Π²Π»Π΅Π½Ρ‹ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹ примСнСния Π² комплСксном Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ 79 Π΄Π΅Ρ‚Π΅ΠΉ, Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… атопичСским Π΄Π΅Ρ€ΠΌΠ°Ρ‚ΠΈΡ‚ΠΎΠΌ, узкополосной срСднСволновой Π£Π€Π’-Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ (311 Π½ΠΌ). ΠšΡƒΡ€Ρ лСчСния состоял ΠΈΠ· 15-20 ΠΏΡ€ΠΎΡ†Π΅Π΄ΡƒΡ€ Π£Π€Π’-Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ (311 Π½ΠΌ) с максимальной Ρ€Π°Π·ΠΎΠ²ΠΎΠΉ Π΄ΠΎΠ·ΠΎΠΉ облучСния Π½Π΅ Π±ΠΎΠ»Π΅Π΅ 0,15 Π”ΠΆ/см2. Π“Ρ€ΡƒΠΏΠΏΠ° сравнСния (35 Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ…) ΠΏΠΎΠ»ΡƒΡ‡Π°Π»Π° Ρ‚Ρ€Π°Π΄ΠΈΡ†ΠΈΠΎΠ½Π½ΡƒΡŽ Ρ‚Π΅Ρ€Π°ΠΏΠΈΡŽ с использованиСм стандартных Π΄ΠΎΠ· ΠΈ схСм ΠΏΡ€ΠΈΠ΅ΠΌΠ° лСкарствСнных ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ² ΠΈ Π½Π΅ ΠΎΡ‚Π»ΠΈΡ‡Π°Π»Π°ΡΡŒ ΠΎΡ‚ основной Π³Ρ€ΡƒΠΏΠΏΡ‹ ΠΏΠΎ возрасту Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ…, Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΠΈ ΠΈ Ρ„ΠΎΡ€ΠΌΠ΅ заболСвания. ΠšΠ»ΠΈΠ½ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠ΅ индСксов SCORAD, Π”Π˜Π¨Π‘ ΠΈ Π”Π”Π˜ΠšΠ–. УстановлСна высокая ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ узкополосной срСднСволновой Π£Π€Π’-Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ (311 Π½ΠΌ), ΠΎ Ρ‡Π΅ΠΌ ΡΠ²ΠΈΠ΄Π΅Ρ‚Π΅Π»ΡŒΡΡ‚Π²ΡƒΠ΅Ρ‚ Π±ΠΎΠ»Π΅Π΅ Ρ€Π°Π½Π½Π΅Π΅, Ρ‡Π΅ΠΌ Π² Π³Ρ€ΡƒΠΏΠΏΠ΅ сравнСния, ΡƒΠΌΠ΅Π½ΡŒΡˆΠ΅Π½ΠΈΠ΅ клиничСских симптомов, Ρ‡Ρ‚ΠΎ ΠΏΠΎΠ΄Ρ‚Π²Π΅Ρ€ΠΆΠ΄Π°Π»ΠΎΡΡŒ ΡƒΠΌΠ΅Π½ΡŒΡˆΠ΅Π½ΠΈΠ΅ΠΌ Π°Π±ΡΠΎΠ»ΡŽΡ‚Π½Ρ‹Ρ… Π²Π΅Π»ΠΈΡ‡ΠΈΠ½ индСксов SCORAD, Π”Π˜Π¨Π‘ (

    Об ΡΠ½Π΄ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ дисфункции ΠΈ Π΅Π΅ тСрапСвтичСской ΠΊΠΎΡ€Ρ€Π΅ΠΊΡ†ΠΈΠΈ Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… псориазом

    Get PDF
    Goal. To assess the effect of a combined cytostatic therapy and sulodexide on the functional condition of the vascular endothelium in psoriatic patients. Materials and methods. The authors examined 74 patients suffering from psoriasis vulgaris and exudative form of psoriasis. Depending on the treatment option, the patients were subdivided into two groups: Group I (n = 41) receiving a cytostatic therapy and Group II where patients received sulodexide as well. The severity of the endothelium dysfunction was assessed based on laboratory assessments such as nitrogen oxide and endothelin 1 in the blood serum. Results. Prior to the treatment, the level of nitrogen oxide was reduced and endothelin 1 was increased in the blood serum of most patients. Substantial improvement of the pathological process was observed in patients from Group I after the cytostatic therapy (total dose of methotrexate: 100 mg); no normalization of laboratory assessments was observed. In patients from Group II receiving methotrexate (total dose: 40 mg) along with sulodexide, improvement or recovery was observed after the completion of the treatment; endothelium dysfunction was normalized. Conclusion. The inclusion of sulodexide in a complex therapy normalizes endothelial dysfunction in case of psoriasis and reduces the dose and duration of methotrexate treatment.ЦСль. ΠžΡ†Π΅Π½ΠΊΠ° влияния ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡ€ΠΎΠ²Π°Π½Π½ΠΎΠΉ цитостатичСской Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ ΠΈ сулодСксида Π½Π° Ρ„ΡƒΠ½ΠΊΡ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½ΠΎΠ΅ состояниС эндотСлия сосудов Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… псориазом. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. ΠžΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ‹ 74 ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π° с Π²ΡƒΠ»ΡŒΠ³Π°Ρ€Π½ΠΎΠΉ ΠΈ экссудативной Ρ„ΠΎΡ€ΠΌΠ°ΠΌΠΈ псориаза. Π’ зависимости ΠΎΡ‚ ΠΏΡ€ΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Ρ‹ Π±Ρ‹Π»ΠΈ Ρ€Π°Π·Π΄Π΅Π»Π΅Π½Ρ‹ Π½Π° Π΄Π²Π΅ Π³Ρ€ΡƒΠΏΠΏΡ‹: Π±ΠΎΠ»ΡŒΠ½Ρ‹Π΅ 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹ (n = 41) ΠΏΠΎΠ»ΡƒΡ‡Π°Π»ΠΈ Ρ†ΠΈΡ‚ΠΎΡΡ‚Π°Ρ‚ΠΈΡ‡Π΅ΡΠΊΡƒΡŽ Ρ‚Π΅Ρ€Π°ΠΏΠΈΡŽ, Π±ΠΎΠ»ΡŒΠ½Ρ‹ΠΌ 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹ (n = 33) Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎ Π² Π»Π΅Ρ‡Π΅Π½ΠΈΠ΅ Π±Ρ‹Π» Π²ΠΊΠ»ΡŽΡ‡Π΅Π½ сулодСксид. Π’Ρ‹Ρ€Π°ΠΆΠ΅Π½Π½ΠΎΡΡ‚ΡŒ дисфункции эндотСлия ΠΎΡ†Π΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΠΎ Ρ€Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Π°ΠΌ Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ - оксида Π°Π·ΠΎΡ‚Π° ΠΈ эндотСлина-1 Π² сывороткС ΠΊΡ€ΠΎΠ²ΠΈ. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π”ΠΎ лСчСния Ρƒ Π±ΠΎΠ»ΡŒΡˆΠΈΠ½ΡΡ‚Π²Π° ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΡΠ»ΠΎΡΡŒ сниТСниС уровня оксида Π°Π·ΠΎΡ‚Π° ΠΈ ΠΏΠΎΠ²Ρ‹ΡˆΠ΅Π½ΠΈΠ΅ уровня эндотСлина-1 Π² сывороткС ΠΊΡ€ΠΎΠ²ΠΈ. Π—Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ΅ ΡƒΠ»ΡƒΡ‡ΡˆΠ΅Π½ΠΈΠ΅ патологичСского процСсса Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… 1-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹ ΠΎΡ‚ΠΌΠ΅Ρ‡Π°Π»ΠΎΡΡŒ послС провСдСния цитостатичСской Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ (суммарная Π΄ΠΎΠ·Π° мСтотрСксата 100 ΠΌΠ³), Ρ‚Π΅Π½Π΄Π΅Π½Ρ†ΠΈΠΈ ΠΊ Π½ΠΎΡ€ΠΌΠ°Π»ΠΈΠ·Π°Ρ†ΠΈΠΈ Π»Π°Π±ΠΎΡ€Π°Ρ‚ΠΎΡ€Π½Ρ‹Ρ… ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»Π΅ΠΉ выявлСно Π½Π΅ Π±Ρ‹Π»ΠΎ. Π£ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… 2-ΠΉ Π³Ρ€ΡƒΠΏΠΏΡ‹, ΠΏΠΎΠ»ΡƒΡ‡Π°Π²ΡˆΠΈΡ… мСтотрСксат (суммарная Π΄ΠΎΠ·Π° 40 ΠΌΠ³) Π² комплСксС с сулодСксидом, послС окончания Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ наблюдалось ΡƒΠ»ΡƒΡ‡ΡˆΠ΅Π½ΠΈΠ΅ ΠΈΠ»ΠΈ Ρ€Π°Π·Ρ€Π΅ΡˆΠ΅Π½ΠΈΠ΅ процСсса, Π½ΠΎΡ€ΠΌΠ°Π»ΠΈΠ·ΠΎΠ²Π°Π»ΠΈΡΡŒ ΠΏΠΎΠΊΠ°Π·Π°Ρ‚Π΅Π»ΠΈ дисфункции эндотСлия. Π—Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅. Π’ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡƒΡŽ Ρ‚Π΅Ρ€Π°ΠΏΠΈΡŽ сулодСксида Π½ΠΎΡ€ΠΌΠ°Π»ΠΈΠ·ΡƒΠ΅Ρ‚ ΡΠ½Π΄ΠΎΡ‚Π΅Π»ΠΈΠ°Π»ΡŒΠ½ΡƒΡŽ Π΄ΠΈΡΡ„ΡƒΠ½ΠΊΡ†ΠΈΡŽ ΠΏΡ€ΠΈ псориазС ΠΈ ΠΏΠΎΠΌΠΎΠ³Π°Π΅Ρ‚ ΡƒΠΌΠ΅Π½ΡŒΡˆΠΈΡ‚ΡŒ Π΄ΠΎΠ·Ρƒ ΠΈ Π΄Π»ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ ΠΏΡ€ΠΈΠ΅ΠΌΠ° мСтотрСксата

    Π›ΠΈΠΌΡ„ΠΎΠΌΠ°Ρ‚ΠΎΠΈΠ΄Π½Ρ‹ΠΉ ΠΏΠ°ΠΏΡƒΠ»Π΅Π·

    Get PDF
    Etiology, pathogenesis, clinical and pathomorphological criteria of diagnostics of lymphomatoid papulosis are described. The case of own supervision is presented.ΠžΠΏΠΈΡΠ°Π½Ρ‹ этиология, ΠΏΠ°Ρ‚ΠΎΠ³Π΅Π½Π΅Π·, клиничСскиС ΠΈ патоморфологичСскиС ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠΈ диагностики Π»ΠΈΠΌΡ„ΠΎΠΌΠ°Ρ‚ΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ ΠΏΠ°ΠΏΡƒΠ»Π΅Π·Π°, ΠΏΡ€ΠΈΠ½Ρ†ΠΈΠΏΡ‹ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ заболСвания. ΠŸΡ€ΠΈΠ²Π΅Π΄Π΅Π½ случай собствСнного наблюдСния

    Π›ΠΈΠΏΠΎΠΈΠ΄Π½Ρ‹ΠΉ Π½Π΅ΠΊΡ€ΠΎΠ±ΠΈΠΎΠ· (болСзнь ОппСнгСйма β€” ΡƒΡ€Π±Π°Ρ…Π°)

    Get PDF
    Etiology, pathogenesis, clinical and pathomorphological criteria of diagnostics of necrobiosis lipoidica are described. The case of own supervision is presented.ΠžΠΏΠΈΡΠ°Π½Ρ‹ этиология, ΠΏΠ°Ρ‚ΠΎΠ³Π΅Π½Π΅Π·, клиничСскиС ΠΈ патоморфологичСскиС ΠΊΡ€ΠΈΡ‚Π΅Ρ€ΠΈΠΈ диагностики Π»ΠΈΠΏΠΎΠΈΠ΄Π½ΠΎΠ³ΠΎ Π½Π΅ΠΊΡ€ΠΎΠ±ΠΈΠΎΠ·Π°, ΠΏΡ€ΠΈΠ½Ρ†ΠΈΠΏΡ‹ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ заболСвания. ΠŸΡ€ΠΈΠ²Π΅Π΄Π΅Π½ случай собствСнного наблюдСния

    INTERFERON BETA IN TREATMENT OF DISSEMINATED SCLEROSIS IN ADOLESCENTS β€” INFLUENCE ON NEUROPSYCHOLOGICAL STATUS AND PAROXYSMAL STATES

    No full text
    Disseminated sclerosis is chronic progressive disease of central nervous system, which is characterized by demyelination, degeneration of nerve fibers and polymorphous clinical symptoms. According to literature data, 2–10% of patients have onset of a disease in childhood and adolescence. Frequent clinical symptoms of disseminated sclerosis, especially in adolescents, are paroxysmal states and neuropsychological disorders. Drugs containing interferon beta which are used for immunomodulating treatment, can increase the rate of paroxysmal neuropsychological disorders in patients with disseminated sclerosis. Present study with participation of 78 adolescents analyzed frequency and spectrum of neuropsychological disorders and paroxysmal states in patients 12–17 years old and relation of revealed disorders with a treatment with interferon beta.Key words: adolescents, disseminated sclerosis, interferon beta, treatment, depression, paroxysmal states, anxiety, neuropsychological testing.(Voprosy sovremennoi pediatrii β€”Β Current Pediatrics. – 2010;9(4):34-39)</span

    SAFETY OF INTERFERON BETA 1A FOR A SUBCUTANEOUS ADMINISTRATION IN CHILDREN AND ADOLESCENTS WITH DISSEMINATED SCLEROSIS

    No full text
    The onset of disseminated sclerosis occurs in childhood and juvenile age in 10% of patients. nevertheless, all immunomodulatory drugs for a treatment of this disease intended for adult population of patients, and there's an age limitation to the administration of these medications. There's only one interferon beta in group of Β«changing the clinical course of disseminated sclerosis medicationsΒ», that was annotated to the administration in patients from 16 years. It's interferon betab1a (Rebif) for subcutaneous administration in 22 ?g and 44 ?g dosage. This drug was well known as an effective and safe medication for a long term administration for a long time in adult neurological practice. But doctors have to use interferon betab1a Β«off labelΒ» yet in patients younger 16 years in Russia and in other countries, comparing risk of changing the regimen of age limitation and risk of deprivation of un derbaged patient of years of qualitative life.Key words: children, disseminated sclerosis, interferon beta 1a, treatment
    corecore